Baskaran Subramani

Dr. Baskaran Subramani

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JDJonathan Dao
Jonathan Dao
PCPatrick Joseph Conway
Patrick Joseph Conway
BSBaskaran Subramani
Baskaran Subramani
DMDevi Meyyappan
Devi Meyyappan
SRSammy Russell
Sammy Russell
DMDaruka Mahadevan
Daruka Mahadevan
The detection of circulating tumor DNA (ctDNA) in liquid biopsy samples as an oncological marker is being used in clinical trials at every step of clinical management. As ctDNA-based liquid biopsy kits are developed and used in clinics, companies work towards increased convenience, accuracy, and cost over solid biopsies and other oncological markers. The technology used to differentiate ctDNA and cell-free DNA (cfDNA) continues to improve with new tests and methodologies being able to detect down to mutant allele frequencies of 0.001% or 1/100,000 copies. Recognizing this development in technology, the FDA has recently given pre-market approval and breakthrough device designations to multiple companies. The purpose of this review is to look at the utility of measuring total cfDNA, techniques used to differentiate ctDNA from cfDNA, and the utility of different ctDNA-based liquid biopsy kits using relevant articles from PubMed, clinicaltrials.gov, FDA approvals, and company newsletters. Measuring total cfDNA could be a cost-effective, viable prognostic marker, but various factors do not favor it as a monitoring tool during chemotherapy. While there may be a place in the clinic for measuring total cfDNA in the future, the lack of standardization means that it is difficult to move forward with large-scale clinical validation studies currently. While the detection of ctDNA has promising standardized liquid biopsy kits from various companies with large clinical trials ongoing, their applications in screening and minimal residual disease can suffer from lower sensitivity. However, researchers are working towards solutions to these issues with innovations in technology, multi-omics, and sampling. With great promise, further research is needed before liquid biopsies can be recommended for everyday clinical management.

1 October 2023 in Environmental Research
Verified
Journal Article
Closed access
TPTran Nhat Phuong
Tran Nhat Phuong
NTNguyen Duy Tai
Nguyen Duy Tai
AAAbeer S. Aloufi
Abeer S. Aloufi
BSBaskaran Subramani
Baskaran Subramani
STSridevi Dhanarani Theivaraj
Sridevi Dhanarani Theivaraj

30 September 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
WAWilliam C. Arnold
William C. Arnold
DPDurga Meenakshi Panneerdoss
Durga Meenakshi Panneerdoss
BSBaskaran Subramani
Baskaran Subramani
MMMegharani Mahajan
Megharani Mahajan
BEBehnam Ebrahimi
Behnam Ebrahimi
YLYasmin A Lyons
Yasmin A Lyons
Ovarian cancer (OCa) remains the most lethal gynecologic malignancy in the United States, with low-grade serous and mucinous subtypes frequently driven by KRAS mutations. These mutations activate downstream MAPK and PI3K/AKT signaling pathways, contributing to tumor progression and resistance to therapy. Although the MEK inhibitor trametinib is used to target these pathways, its efficacy is limited in KRAS-mutant OCa due to compensatory activation of the leukemia inhibitory factor (LIF)/LIF receptor (LIFR) axis. In this study, we evaluated the therapeutic potential of combining trametinib with EC359, a selective LIFR inhibitor, in Ras/Raf-driven OCa models. EC359 significantly reduced cell viability, clonogenic survival, and induced cell death via ferroptosis in vitro. Mechanistic studies revealed that EC359 suppressed trametinib-induced activation of LIFR downstream signaling. RNA-seq analysis showed that combination therapy downregulated mitochondrial translation and MYC target genes while upregulating apoptosis-related genes. In vivo, EC359 and trametinib co-treatment significantly reduced tumor growth in xenograft and PDX models without inducing toxicity. Our studies identify LIFR signaling as a critical vulnerability in Ras/Raf-mutant and low grade serous OCa. Further, it provides strong preclinical rationale for EC359 and trametinib combination therapy as a new therapeutic strategy for treating Ras/Raf-driven OCa and low-grade serous OCa.

21 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
BSBaskaran Subramani
Baskaran Subramani
PCPatrick Joseph Conway
Patrick Joseph Conway
AAAisha Al-Khinji
Aisha Al-Khinji
KZKun Zhang
Kun Zhang
Ritu PandeyRitu Pandey
Ritu Pandey
DMDaruka Mahadevan
Daruka Mahadevan
Background/Objectives: Aurora (AK) A/B are oncogenic mitotic kinases that when over-expressed are poor prognostic markers in mantle cell lymphoma (MCL). Methods and Results: Alisertib, an AK-A inhibitor, has anti-tumor activity in relapsed/refractory (r/r) MCL patients. We evaluated alisertib plus ibrutinib in MCL to abrogate ibrutinib resistance. Alisertib plus ibrutinib was therapeutically synergistic on both Granta-519 insensitive to ibrutinib and JeKo-1 cells sensitive to ibrutinib. Alisertib decreased PI-3K, BTK, p38, HCK, and RSK kinases, indicative of its multipotent effect on cellular proliferation and growth. A mouse xenograft model of Granta-519 demonstrated that alisertib plus ibrutinib had a comparable anti-tumor response to ibrutinib plus rituximab. However, alisertib plus ibrutinib plus rituximab demonstrated significantly stronger tumor growth inhibition than the doublets. Conclusions: Both double and triple combinations showed enhanced survival versus ibrutinib alone. Ibrutinib insensitivity can be disrupted by alisertib plus ibrutinib in MCL.

1 October 2026 in Cancer Research Communications
Verified
Journal Article
Open access
DPDurga Meenakshi Panneerdoss
Durga Meenakshi Panneerdoss
KNKhaled Mohamed Nassar
Khaled Mohamed Nassar
BSBaskaran Subramani
Baskaran Subramani
WAWilliam Cole Arnold
William Cole Arnold
SVSai Pranathi Vedagiri Venkata
Sai Pranathi Vedagiri Venkata
RVRatna Vadlamudi
Ratna Vadlamudi
Ovarian cancer remains the most lethal gynecologic malignancy, driven in part by intrinsic and acquired therapeutic resistance to DNA-damaging chemotherapies. We previously demonstrated that ERX-208 targets the protein encoded by lysosomal acid lipase to induce catastrophic endoplasmic reticulum (ER) stress in ovarian cancer models. As ERX-class compounds advance to clinical development, rational combination strategies are needed to maximize therapeutic efficacy. To address this question, we conducted an unbiased in vitro screen of the combination of ERX-208 with 147 FDA-approved agents. We identified that DNA-damaging chemotherapies, including anthracyclines, oxaliplatin, and paclitaxel, were most synergistic in combination with ERX-208. Reanalysis of our transcriptomic data in ovarian cancer cells revealed coordinated suppression of DNA damage repair, DNA replication, and checkpoint pathways following ERX-208 treatment. Together, these data support a narrative that ERX-208 may selectively suppress DNA repair pathways and potentiate cytotoxicity by DNA-damaging agents. To test this hypothesis, we used platinum and paclitaxel, two standard-of-care agents in ovarian cancer. We found that ERX-208 synergized with platinum and paclitaxel across multiple ovarian cancer models, enhancing apoptosis and suppressing proliferation, clonogenicity, and invasion. Mechanistically, combination treatment increased DNA damage and amplified ER stress and apoptotic signaling. Importantly, ERX-208–based combinations showed enhanced antitumor activity in patient-derived explant, and xenograft models. These findings support a model in which ERX-208 impairs DNA damage response pathways and sensitizes ovarian cancer cells to DNA-damaging chemotherapy. Collectively, these findings provide a strong rationale for the combination strategy in clinical translation. Significance: This study demonstrates the clinical utility of ERX-208 in enhancing chemotherapy efficacy in ovarian cancer. By inducing sustained ER stress and a functional DNA repair–deficient state, ERX-208 sensitizes treatment-naïve and treatment-resistant tumors to platinum and taxanes. Findings support the rapid clinical development of ERX-class combinations, offering a rationale for pairing with standard regimens. This strategy may enable dose reduction, overcome resistance, expand options, and support biomarker-guided patient selection.